Propanc Biopharma (PPCB) Stock Price, News & Analysis

Company Overview

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Key Stats

• Today's Range: $3.00 to $3.24
• 50-Day Range: $2.87 to $10.40
• 52-Week Range: $1.25 to $145.46
• Volume: 181,208 shs
• Average Volume: 867,348 shs
• Market Capitalization: $35.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PPCB Stock Analysis - Frequently Asked Questions

How have PPCB shares performed this year?

Propanc Biopharma's stock was trading at $0.0002 at the beginning of the year. Since then, PPCB stock has increased by 1,559,900.0% and is now trading at $3.12.

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma Inc (OTCMKTS:PPCB) released its quarterly earnings results on Thursday, May, 15th. The company reported ($12.50) earnings per share (EPS) for the quarter.

When did Propanc Biopharma's stock split?

Propanc Biopharma's stock reverse split before market open on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

When does Propanc Biopharma's quiet period expire?

Propanc Biopharma's quiet period expires on Wednesday, September 24th. Propanc Biopharma had issued 1,000,000 shares in its initial public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. During Propanc Biopharma's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PPCB
• CIK: 1517681
• Web: www.propanc.com
• Phone: (139) 882-0780
• Fax: 61 03 9882 9969
• Employees: 1
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,652.66%
• Return on Assets: -971.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.24
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($493.34) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 11,612,000
• Free Float: 19,000
• Market Cap: $35.07 million
• Optionable: Not Optionable
• Beta: 2.78